Abstract
N-Methyl-D-aspartate (NMDA) antagonists induce psychotomimetic effects in humans that closely resemble negative and cognitive symptoms of schizophrenia. NMDA agonists, in contrast, may significantly ameliorate such symptoms. In rodents, phencyclidine (PCP) and other NMDA antagonists induce a hyperlocomotory syndrome that is reversed by NMDA agonists. The present study investigates the mechanism of action of glycyldodecylamide (GDA), a drug that is 80-fold more potent than glycine in reversing PCP-induced hyperactivity in rodents. At concentrations relevant to its behavioral actions, GDA significantly inhibits forebrain glycine uptake, indicating that glycine uptake inhibition may provide effective treatment for PCP psychosis and PCP psychosis-like symptoms of schizophrenia.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
